Home > Neurology > MTIS 2020 > Contents > Early initiation of lasmiditan improves migraine outcomes

Early initiation of lasmiditan improves migraine outcomes

Presented By
Dr Mario F. Peres, Hospital Israelita Albert Einstein, Brazil

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
MTIS 2020
Trial
Phase 3, GLADIATOR
The open-label, 12-month, phase 3 GLADIATOR trial evaluated the efficacy of the novel, selective 5-HT1F receptor agonist lasmiditan in treating migraine attacks of mild versus moderate or severe pain severity [1]. Treating migraine attacks at mild pain showed a tendency to relatively better efficacy outcomes, suggesting that earlier dosing is beneficial. It is recommended to treat acute migraine attacks early, when pain is mild. In two phase 3, placebo-controlled, single-attack clinical trials (SAMURAI and SPARTAN), lasmiditan was superior to placebo in treating moderate-to-severe migraine attacks. However, few mild attacks were stu...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on